CHA
ALT icon

Carmichael Hill & Associates’s Altimmune ALT Stock Holding History

Carmichael Hill & Associates’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-729
Closed -$9K – 786
2022
Q3 		$9K Buy
+729
New +$10.8K ﹤0.01% 578

Other funds holding ALT

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Carmichael Hill & Associates's ALT Position: Q4 2022 in Review

Carmichael Hill & Associates sold out of Altimmune (ALT) in Q4 2022, closing a stake of 729 shares — an estimated $9K sold.

Carmichael Hill & Associates first reported a position in ALT in Q3 2022 and held it in 1 quarter. The position peaked at $9K in Q3 2022. 128 funds tracked by Wall St. Rank hold ALT as of Q4 2022.

  • Carmichael Hill & Associates reported no remaining Altimmune position as of Q4 2022 after selling out during the quarter.
  • Carmichael Hill & Associates sold 729 Altimmune shares in Q4 2022, an estimated $9K.
  • Carmichael Hill & Associates first reported a position in Altimmune in Q3 2022 and held it in 1 quarter.
  • Carmichael Hill & Associates's Altimmune position peaked at $9K in Q3 2022.
  • 128 funds tracked by Wall St. Rank held Altimmune as of Q4 2022.

Based on Carmichael Hill & Associates's 13F filing for Q4 2022, filed 14 Feb 2023.